- Trump Could Ensure Democratic Dominance for Years
- Reports Claim Alabama Governor Had an Affair
- Bonus Trump Quote of the Day
- Why Is Jeb Bush Going After Donald Trump?
- Trump and Clinton Maintain Wide Leads in Iowa
By Paul Jenks Posted at 10:30 a.m. on July 29, 2014
The Food and Drug Administration on Monday issued a notice seeking comments on the process of naming prescription drugs, particularly drug manufacturers’ desire to reserve a specific name for a drug product.
The naming process for a drug is normally associated with the regular approval process. The drug safety agency, which is keen on making sure the name of the product does not promote medication errors, earlier this year issued guidance on drug naming.
However, the FDA – spurred by negotiations with industry groups and Congress ahead of a 2007 FDA drug user fee reauthorization law – is considering the idea of reserving drug names ahead of the final approval of a drug.
Here’s a useful primer on how drugs are named from Dr. Suzanne Koven on Boston.com.
Healthopolis covers the health care community in Washington and beyond the Beltway.
Paul Jenks (@PHJenks) leads the coverage for Healthopolis. He also serves as a news and analytics editor for CQ Now, providing real-time coverage of congressional activity.
Adriel Bettelheim (@abettel), John Reichard (@CQHealthTweet), Rebecca Adams (@RebeccaAdamsDC) and Kerry Young (@KDooleyYoung) — who collectively edit and write for CQ HealthBeat, also write for Healthopolis.
More news from CQ Now
More news from CQ Healthbeat